首页> 外文期刊>Tropical Journal of Pharmaceutical Research >Development and Validation of a RP-HPLC Method for Assay of Atorvastatin and its Application in Dissolution Studies on Thermosensitive Hydrogel-Based Nanocrystals
【24h】

Development and Validation of a RP-HPLC Method for Assay of Atorvastatin and its Application in Dissolution Studies on Thermosensitive Hydrogel-Based Nanocrystals

机译:RP-HPLC法测定阿托伐他汀的开发,验证及其在热敏水凝胶基纳米晶体溶解研究中的应用

获取原文
           

摘要

Purpose: To develop and validate a novel reverse phase high performance liquid chromatographic (RP-HPLC) method for the quantification of atorvastatin in thermosensitive hydrogel-based nanocrystal formulation. Method: Chromatographic identification was achieved on C18 (5 μm) column using acetonitrile and 0.025 M potassium dihydrogen ortho-phosphate buffer pH 5 (45:55 v/v) as mobile phase, at a flow rate of 1.5 mL/min and using photo diode array detector (PDA) at 246 nm. The developed HPLC method was validated according to International Conference on Harmonisation (ICH) Q2(R1) guidelines and applied to dissolution studies on atorvastatin thermosensitive hydrogel-based nanocrystal formulation, using Lipitor? as standard. Results: Determination was successfully achieved with good peak resolution from atorvastatin nanocrystals and a commercial formulation brand (Lipitor? tablets) without interference of polymer or excipients. The retention time of atorvastatin was 4.5 min and drug response was linear in the range of 0.1 - 0.5 μg/mL with a correlation coefficient of 0.9995. Precision was determined to be between 0.16 - 0.61 percent relative standard deviation (% RSD) for the analyzed samples. The limit of detection and of quantification was 35.6 and 71.2 ng/mL, respectively, which was 10 times higher than a previously reported method. The assay of atorvastatin nanocrystal and Lipitor? gave 99.37 and 99.12 % recovery, respectively. Dissolution studies showed atorvastatin release of 40 and 65 % at 40 min from thermosensitive hydrogel nanocrystal formulation and Lipitor?, respectively indicating sustained release. Conclusion: The method is successfully validated and is specific, linear, precise, and accurate with good robustness. It is applicable to atorvastatin nanocrystal dissolution studies and is a promising quality control tool for atorvastatin analysis in nanoformulations and pharmaceutical dosage forms.
机译:目的:建立并验证一种新型的反相高效液相色谱(RP-HPLC)方法,用于定量基于热敏水凝胶的纳米晶体制剂中的阿托伐他汀。方法:在C18(5μm)色谱柱上,使用乙腈和0.025 M正磷酸二氢钾缓冲液pH 5(45:55 v / v)作为流动相,以1.5 mL / min的流速并使用光敏剂,进行色谱鉴定二极管阵列检测器(PDA)在246 nm处。所开发的HPLC方法已根据国际协调会议(ICH)Q2(R1)指南进行了验证,并用于使用Lipitor?的阿托伐他汀热敏水凝胶基纳米晶体制剂的溶出度研究。作为标准。结果:阿托伐他汀纳米晶体和商业品牌商标(Lipitor?片剂)以良好的峰分离度成功完成了测定,而没有聚合物或赋形剂的干扰。阿托伐他汀的保留时间为4.5分钟,药物反应在0.1-0.5μg/ mL范围内呈线性,相关系数为0.9995。经测定,精密度在相对标准偏差(%RSD)的0.16%-0.61%之间。检测限和定量限分别为35.6和71.2 ng / mL,比以前报道的方法高10倍。阿托伐他汀纳米晶体和立普妥的含量测定回收率分别为99.37和99.12%。溶出度研究表明,在40分钟时,阿托伐他汀从热敏性水凝胶纳米晶体制剂和立普妥TM中释放40%和65%,分别表明持续释放。结论:该方法已成功验证,并且具有特异性强,线性好,精确度高,准确度高,鲁棒性强等优点。它适用于阿托伐他汀纳米晶体的溶出度研究,是用于纳米制剂和药物剂型中阿托伐他汀分析的有前途的质量控制工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号